ChengDa Pharmaceuticals Co. Ltd. Total Assets
ChengDa Pharmaceuticals Co. Ltd. total assets. Based on the latest financial reports, ChengDa Pharmaceuticals Co. Ltd. (301201) holds total assets worth CN¥2.35 Billion CNY (≈ $343.98 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 301201 market cap for the company's overall valuation and market capitalisation.
Total Assets of ChengDa Pharmaceuticals Co. Ltd. (2019–2025)
Total assets of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025. This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. See ChengDa Pharmaceuticals Co. Ltd. share price for real-time trading data and today's change.
ChengDa Pharmaceuticals Co. Ltd. - Asset Composition Analysis
ChengDa Pharmaceuticals Co. Ltd. Total Assets Breakdown (December 2025)
ChengDa Pharmaceuticals Co. Ltd. total assets breakdown as of December 2025. ChengDa Pharmaceuticals Co. Ltd.'s total assets of CN¥2.35 Billion consist of 55.5% current assets and 44.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 30.9% |
| Accounts Receivable | CN¥107.73 Million | 4.6% |
| Inventory | CN¥148.43 Million | 6.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥37.16 Million | 1.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how ChengDa Pharmaceuticals Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ChengDa Pharmaceuticals Co. Ltd. current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ChengDa Pharmaceuticals Co. Ltd.'s current assets represent 55.5% of total assets in 2025, an increase from 41.6% in 2019.
- Cash Position: Cash and equivalents constituted 30.9% of total assets in 2025, up from 12.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 6.3% of total assets.
ChengDa Pharmaceuticals Co. Ltd. Competitors by Total Assets
Key competitors of ChengDa Pharmaceuticals Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
ChengDa Pharmaceuticals Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.53 | 8.95 | 22.78 |
| Quick Ratio | 5.71 | 7.99 | 21.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.12 Billion | CN¥1.26 Billion | CN¥1.69 Billion |
ChengDa Pharmaceuticals Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between ChengDa Pharmaceuticals Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.53 |
| Latest Market Cap to Assets Ratio | 0.23 |
| Asset Growth Rate (YoY) | -3.6% |
| Total Assets | CN¥2.35 Billion |
| Market Capitalization | $539.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values ChengDa Pharmaceuticals Co. Ltd.'s assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: ChengDa Pharmaceuticals Co. Ltd.'s assets decreased by 3.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for ChengDa Pharmaceuticals Co. Ltd. (2019–2025)
The table below shows the annual total assets of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.35 Billion ≈ $343.86 Million |
-3.55% |
| 2024-12-31 | CN¥2.44 Billion ≈ $356.53 Million |
-0.77% |
| 2023-12-31 | CN¥2.46 Billion ≈ $359.29 Million |
+5.75% |
| 2022-12-31 | CN¥2.32 Billion ≈ $339.77 Million |
+239.84% |
| 2021-12-31 | CN¥683.23 Million ≈ $99.98 Million |
+27.90% |
| 2020-12-31 | CN¥534.21 Million ≈ $78.17 Million |
-2.26% |
| 2019-12-31 | CN¥546.56 Million ≈ $79.98 Million |
-- |
About ChengDa Pharmaceuticals Co. Ltd.
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and A… Read more